Massage may ease chemo nerve damage
NCT ID NCT02221700
First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 1 time
Summary
This study looks at whether massage therapy can reduce nerve problems like pain, numbness, and tingling caused by chemotherapy in people with breast or digestive system cancers. About 90 participants will receive massage sessions to see if it improves symptoms and quality of life. The goal is to find a gentle, drug-free way to manage these side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 90 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2015
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All gastrointestinal malignancies where the patient received oxaliplatin for cancer treatment or breast malignancies where patients have received docetaxel or paclitaxel for cancer treatment * Greater or equal to 6 months from last chemotherapy treatment * Must understand and read English, sign a written informed consent, and follow protocol requirements * Must be willing to come to MD Anderson Main Campus (Texas Medical Center) for intervention * Lower extremity neuropathy per patient report attributable to oxaliplatin, docetaxel or paclitaxel (neurotoxic chemotherapeutic agent) as determined by patient history of neurotoxic agent administration and no history of other attributable causes such as diabetic neuropathy * Patient self-report neuropathy score greater than or equal to 3 on a 0 to 10 numeric scale and/or grade 2 or 3 neuropathy (according to the National Cancer Institute Common Toxicity Criteria 4 point grading scale) * Within 2 weeks prior to study enrollment the patient must be on a stable dose of medications for management of chemotherapy-induced peripheral neuropathy (CIPN) symptoms; for at least 2 weeks prior to enrollment stable dose is defined as: * No change in drug class * Increases or decreases that are less than or equal to 20% of the total dosage; all drug classes are allowed Exclusion Criteria: * Patients with previously diagnosed peripheral neuropathy pre-dating their neurotoxic chemotherapy administration or from causes other than chemotherapy * Platelets less than 50,000 within 6 months prior to study enrollment or * Neutrophil count less than 500 within 6 months prior to study enrollment * Deep venous thrombosis (DVT) diagnosed within 12 months of study enrollment or history or untreated lower extremity DVT, bone metastases, currently active skin infection, or lymphedema currently involving the treatment field * Women who are pregnant at time of enrollment; pregnancy will be assessed at enrollment using urine pregnancy test * Diagnosis of diabetes
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chemotherapy-induced peripheral neuropathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a vaccine stop GI cancers from returning?
- Can TENS, compression, or cold therapy stop chemo nerve pain?
- Robots map how brain and nerve injuries disrupt everyday arm tasks
- Cold therapy may offer relief for Chemotherapy-Induced nerve pain in children
- Can an antidepressant calm Chemotherapy's nerve pain?
- Retraining the senses to fight chemotherapy nerve damage